OCA 0.1mg ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 296 | 胆道閉鎖症 | 1 |
296. 胆道閉鎖症
臨床試験数 : 71 / 薬物数 : 70 - (DrugBank : 39) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 60
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05321524 (ClinicalTrials.gov) | July 1, 2015 | 18/3/2022 | Obeticholic Acid in Pediatric Subjects With Biliary Atresia | A Multicenter, Open-Label, Single- and Multiple-Dose, Dose-Finding Study, With an Optional Open-Label Extension to Assess the Safety, Tolerability, and Pharmacokinetics of Obeticholic Acid in Pediatric Subjects With Biliary Atresia | Biliary Atresia | Drug: OCA 0.1mg;Drug: OCA 1.5mg;Drug: OCA 5mg | Intercept Pharmaceuticals | NULL | Active, not recruiting | 2 Years | 17 Years | All | 32 | Phase 2 | Belgium;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom |